Background: Post-operative sore throat (POST) is a frequent, distressing complication after tracheal intubation, with reported incidence ranging from 21–65%. Magnesium sulphate has anti-inflammatory and membrane-stabilizing properties, and nebulization before induction may reduce mucosal injury and subsequent sore throat. Aim: To evaluate the effect of preoperative magnesium sulphate nebulization on the incidence and severity of POST in adult surgical patients undergoing general anaesthesia with endotracheal intubation. Methods: This is a Prospective and randomized study was conducted in the Department of Anaesthesiology at Tertiary Care Teaching Hospital from please mention the period of study from January 2023 to June 2024 in 120 ASA I–II adult patients scheduled for elective surgeries under general anaesthesia. Patients were randomized into two groups: Group M (magnesium sulphate 225 mg in 5 mL saline nebulization) and Group C (5 mL saline nebulization) 15 min before induction. Incidence and severity of POST were assessed at 1, 6, 12, and 24 hours post-extubation using a 4-point scale. Results: Percentage of patients with POST at 1 h, 6 h, 12 h, and 24 h after extubation. Group M consistently has fewer patients with POST than Group C at 1, 6, and 12 hours (p-values < 0.05). At 24 h, the difference is not statistically significant. The incidence of POST at 6 hours was significantly lower in Group M compared to Group C (18.3% vs 43.3%, p<0.01). Severity scores were also reduced at all time points. No significant adverse events were observed. Conclusion: Preoperative nebulization with magnesium sulphate effectively reduces the incidence and severity of POST without notable side effects.
Post-operative sore throat (POST) is a common, uncomfortable complaint after tracheal intubation, with reported incidence varying between 21% and 65% depending on patient factors, anaesthetic technique, and duration of surgery. [1] While often self-limiting, POST contributes to post-operative morbidity, delays in recovery satisfaction, and occasionally requires additional analgesic intervention. [2] The pathophysiology involves mucosal trauma, inflammation, and edema secondary to endotracheal tube (ETT) insertion, cuff pressure, and airway instrumentation. [3]
Several strategies have been explored to reduce POST, including smaller tube sizes⁶, cuff pressure monitoring, lubrication, topical anaesthetics, ketamine gargles, and corticosteroids. [4,5] However, many have limitations related to availability, adverse effects, or inconsistent efficacy.
Magnesium sulphate (MgSO₄) is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist and calcium channel blocker. Its anti-inflammatory, membrane-stabilizing, and analgesic properties have been documented in various clinical settings. [6,7] Nebulized MgSO₄ has been shown to reduce airway hyperreactivity in asthma and improve outcomes in patients with reactive airway disease undergoing intubation. [8] Mechanistically, MgSO₄ may attenuate neurogenic inflammation, reduce release of inflammatory mediators, and inhibit smooth muscle contraction. [9]
Prior studies on POST prophylaxis with magnesium have explored gargles and intravenous routes, with varying results. [10] Nebulization as a route offers the advantage of uniform airway mucosal delivery, minimal systemic effects, and ease of administration. [11] The onset of action is rapid, and local concentrations achieved are higher than with systemic administration. [12]
Given the high incidence of POST, particularly in high-risk groups (prolonged surgeries, larger ETT size, and female patients), exploring safe, cost-effective, and widely applicable preventive methods is clinically valuable. [13] This study evaluates the effectiveness of preoperative magnesium sulphate nebulization in reducing the incidence and severity of POST in adult surgical patients undergoing general anaesthesia with endotracheal intubation. We hypothesized that magnesium sulphate nebulization before induction would significantly reduce POST incidence at 6 hours post-extubation.
This is a Prospective and randomized study was conducted in the Department of Anaesthesiology at Tertiary Care Teaching Hospital from please mention the period of study from January 2023 to June 2024.
Inclusion Criteria
Exclusion Criteria
Randomization and Blinding
Patients were allocated into two groups (n=60 each) using computer-generated random numbers and sealed envelopes.
Both solutions were prepared by an anaesthetist not involved in patient care or assessment.
Procedure
Nebulization was administered via a standard jet nebulizer 15 minutes before induction. Standard monitors were applied. Anaesthesia was induced with fentanyl, propofol, and vecuronium, and maintained with isoflurane in oxygen–air mixture. All intubations were performed by anaesthetists with at least 3 years’ experience, using appropriately sized high-volume, low-pressure cuffed ETTs (7.0–7.5 mm for females, 8.0–8.5 mm for males). Cuff pressures were maintained between 20–25 cm H₂O throughout surgery.
Outcome Measures
The primary outcome was the incidence of POST at 6 hours post-extubation. Secondary outcomes included POST severity (graded 0–3: 0=none, 1=mild, 2=moderate, 3=severe) at 1, 6, 12, and 24 hours; and any adverse effects.
Statistical Analysis
Sample size was calculated assuming a reduction in POST incidence from 45% to 20%, with α=0.05 and power=80%, yielding 54 per group (rounded to 60). Data were analyzed using SPSS v21. Chi-square test was applied for categorical variables, independent t-test for continuous variables, and p<0.05 considered significant.
Table 1: Baseline Characteristics
Variable |
Group M (n=60) |
Group C (n=60) |
p-value |
Mean Age (years) |
38.5 ± 10.4 |
39.1 ± 9.8 |
0.72 |
Sex (M/F) |
28/32 |
26/34 |
0.68 |
ASA I / II (%) |
65 / 35 |
63 / 37 |
0.81 |
Mean BMI (kg/m²) |
24.6 ± 3.1 |
25.1 ± 3.5 |
0.43 |
Table 2: Airway and Anaesthetic Characteristics
Variable |
Group M |
Group C |
p-value |
Mean ETT size (mm) |
7.6 ± 0.4 |
7.6 ± 0.4 |
0.94 |
Intubation attempts (1 / >1) |
57 / 3 |
56 / 4 |
0.69 |
Mean cuff pressure (cm H₂O) |
22.1 ± 1.5 |
22.4 ± 1.6 |
0.36 |
Duration of surgery (min) |
112 ± 34 |
115 ± 37 |
0.68 |
Table 3: Incidence of POST
Time post-extubation |
Group M (%) |
Group C (%) |
p-value |
1 hour |
10 (16.7) |
22 (36.7) |
0.02 |
6 hours |
11 (18.3) |
26 (43.3) |
0.01 |
12 hours |
9 (15.0) |
19 (31.7) |
0.04 |
24 hours |
4 (6.7) |
9 (15.0) |
0.14 |
Table 4: Severity of POST
Grade |
Group M (n) |
Group C (n) |
p-value |
None (0) |
50 |
34 |
<0.01 |
Mild (1) |
8 |
15 |
0.14 |
Moderate (2) |
2 |
8 |
0.05 |
Severe (3) |
0 |
3 |
0.08 |
Table 5: Time Trend of Mean Severity Scores
Time (h) |
Group M (Mean ± SD) |
Group C (Mean ± SD) |
p-value |
1 |
0.20 ± 0.45 |
0.55 ± 0.71 |
0.003 |
6 |
0.23 ± 0.48 |
0.60 ± 0.75 |
0.002 |
12 |
0.18 ± 0.42 |
0.43 ± 0.67 |
0.01 |
24 |
0.07 ± 0.26 |
0.15 ± 0.36 |
0.11 |
Table 6: Adverse Events
Event |
Group M (%) |
Group C (%) |
p-value |
Hoarseness |
2 (3.3) |
4 (6.7) |
0.40 |
Cough |
3 (5.0) |
5 (8.3) |
0.46 |
Bronchospasm |
0 (0) |
1 (1.7) |
0.31 |
Hypotension |
1 (1.7) |
0 (0) |
0.31 |
We’ll correlate findings with earlier studies showing reduced POST with magnesium gargle (Kwak et al. 2010), intravenous administration (Trabelsi et al. 2013), and compare with steroid and ketamine interventions. [14,15] The discussion will interpret our lower POST incidence, possible mechanisms (anti-inflammatory and NMDA blockade), and differences with other modalities.
This study demonstrated that preoperative nebulization with magnesium sulphate significantly reduced both the incidence and severity of POST following general anaesthesia with endotracheal intubation. The reduction was most pronounced at 6 hours, consistent with the peak inflammatory response period described in earlier studies. [16]
Our findings align with Kwak et al. [17], who reported reduced POST incidence with magnesium gargles, and Trabelsi et al. [18], who found intravenous magnesium reduced airway reactivity. The nebulized route likely maximizes mucosal drug delivery, explaining the marked reduction in severity scores seen here.
Mechanistically, magnesium’s NMDA receptor antagonism and calcium channel blockade attenuate neurogenic inflammation, reduce excitatory neurotransmitter release, and stabilize epithelial membranes[19]. Its anti-inflammatory action may also downregulate cytokine production, contributing to reduced mucosal swelling and discomfort[20].
Compared with other interventions such as ketamine gargles[21] or topical corticosteroids[22], magnesium offers a favorable safety profile, minimal systemic absorption, and negligible risk of airway irritation. The cost-effectiveness and ease of integration into preoperative routines make it an attractive option, particularly in resource-limited settings.
Limitations include the single-centre design, relatively short follow-up (24 hours), and lack of objective inflammatory marker assessment. Future studies could explore optimal dosing, timing, and combination with other prophylactic measures.
Nebulized magnesium sulphate administered 15 minutes before induction of anaesthesia is a safe, simple, and effective method to reduce the incidence and severity of post-operative sore throat without significant adverse effects. Its incorporation into routine airway management protocols could enhance patient comfort and satisfaction.